ArticleJournal of translational medicine2025
Cerebrospinal fluid sTREM2 mediates the associations of α-synuclein with tau pathology in older adults without dementia: two population-based study.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- TREM2 as a central hub of neuroimmune-metabolic crosstalk in central nervous system disorders: from microglial biology to therapeutic targeting.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThe role of microglial activation by α-synuclein in Alzheimer’s disease (AD) remains unclear. This study aimed to evaluate the role of soluble triggering receptor expressed on myeloid cells 2 (sTREM2) in regulating the relationship between α-synuclein and tau pathology in cerebrospinal fluid (CSF).
methodsA total of 989 participants were included in the CABLE (Chinese Alzheimer’s Biomarker and LifestylE) study. Multiple linear regression analyses were performed to assess the associations of CSF α-synuclein and sTREM2 with tau pathology. Causal mediation analyses with 10,000 bootstrap iterations were conducted to investigate the mediating effect of sTREM2 on the relationship between α-synuclein and tau pathology. Additionally, subgroup analyses were performed based on APOE ε4 carrier status. The same analytical method was applied to the ADNI (Alzheimer’s Disease Neuroimaging Initiative) cohort for validation. Furthermore, Cox proportional hazards models were employed to evaluate the longitudinal association between α-synuclein levels and the risk of AD in the ADNI cohort. Causal mediation analysis further evaluated the mediating role of tau pathology in the relationship between α-synuclein and the risk of AD.
resultsIn CABLE, elevated levels of α-synuclein were significantly associated with increased levels of sTREM2 (p < 0.001), p-tau181 (p < 0.001), and T-tau (p < 0.001). The relationship between α-synuclein and tau pathology was partially mediated by sTREM2, with mediation rates of 4.8% and 6.3%, respectively. Further subgroup analysis revealed that this mediating relationship was present only in APOE ε4 non-carriers. The CABLE findings were validated in the ADNI, with the proportion of mediators ranging from 17.1 to 18.8%. Additionally, higher levels of α-synuclein were linked to an increased risk of AD (hazard ratio = 2. 137, p = 0.006). The relationship between α-synuclein levels and the risk of AD was mediated by p-tau181 but not T-tau, with a mediation rate of 67.6%.
conclusionsOverall, activated microglia partially mediate the α-synuclein-tau pathology association, while p-tau181 further mediates the relationship between α-synuclein and AD risk. Thus, targeting the CSF α-synuclein-microglia-tau pathological pathway provides new insights into the prevention and treatment of AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.